日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Poly ADP Ribose Polymerase Inhibitors Potentiate Proton Therapy End-of-Range Effects by Accelerating Replication Forks and Promoting Transcription Conflict

聚ADP核糖聚合酶抑制剂通过加速复制叉和促进转录冲突来增强质子治疗的射程末端效应

Han, Yiqun; Zhou, Qin; Dibbs, Anna; Chen, Bin; Weiskittel, Taylor M; Remmes, Nicholas B; Wu, Zheming; Ebner, Daniel K; Kloeber, Jake A; Callaghan, Cameron M; Bendel, Anne E; Mullikin, Trey C; Laack, Nadia N; Xu-Welliver, Meng; Lou, Zhenkun; Mutter, Robert W

Parkin deficiency promotes colorectal tumorigenesis and progression through RIPK3-dependent necroptotic inflammation

Parkin 缺陷通过 RIPK3 依赖性坏死性炎症促进结直肠肿瘤的发生和发展。

Wu, Zheming; Xiao, Huaping; Kloeber, Jake A; Ouyang, Yaobin; Yin, Ping; Huang, Jinzhou; Chen, Bin; Zhu, Shouhai; Lu, Jing; Han, Yiqun; Tu, Xinyi; Dragojevic, Sonja; Luo, Kuntian; Ting, Adrian T; Welliver, Meng; Lou, Zhenkun

Human adaptation to high altitude: acclimatization and reversibility of haemodynamics

人类对高海拔的适应:血液动力学的适应性和可逆性

Xu, Yifan; Hua, Qiaoyi; Chen, Wu; Gong, Jicheng; Meng, Xin; Wang, Teng; Han, Yiqun; Zhang, Yi; He, Xudong; Ye, Chunxiang; Dunzhu, Pubu; Wu, Cencen; Fan, Yuanyuan; Zu, Lingyun; Zhu, Tong

Isoform-specific function of NSD3 in DNA replication stress confers resistance to PARP inhibitors in prostate cancer.

NSD3 在 DNA 复制压力中的亚型特异性功能赋予前列腺癌细胞对 PARP 抑制剂的耐药性

Zhu Shouhai, Gao Huanyao, Jiang Dan, Guo Guijie, Hou Jing, Han Yiqun, Zhang Chao, Hu Xiaoping, Indulkar Shreya, Kloeber Jake A, Hu Qi, Jiang Yanxia, Zeng Xiangyu, Ouyang Yaobin, Lu Jing, Yin Ping, Luo Kuntian, Huang Jinzhou, Wu Zheming, Chen Bin, Xiao Huaping, Dragojevic Sonja, Qin Hongran, Zhou Xiang, Jin Jian, Tu Xinyi, Wang Liewei, Lou Zhenkun

Clinical Differences Among Histological Categories of Sarcoma: Insights from 97,062 Patients

肉瘤组织学类型之间的临床差异:来自 97,062 例患者的研究结果

Han, Yiqun; Shah, Ahmed; Yao, Yuan; Mutter, Robert W; Xu-Welliver, Meng

Outcomes of immune checkpoint inhibitor rechallenge in relapsed/refractory Hodgkin lymphoma

免疫检查点抑制剂再次治疗复发/难治性霍奇金淋巴瘤的疗效

Nishimura, Yoshito; Han, Yiqun; Toumeh, Nadia; Janda, Guneet; Fujiwara, Yu; Durani, Urshila; Nowakowski, Grzegorz S; Paludo, Jonas; Ansell, Stephen M; Abeykoon, Jithma P

Disitamab vedotin, a HER2-directed antibody-drug conjugate, in patients with HER2-overexpression and HER2-low advanced breast cancer: a phase I/Ib study

Disitamab vedotin(一种靶向 HER2 的抗体药物偶联物)用于治疗 HER2 过表达和 HER2 低表达的晚期乳腺癌患者:一项 I/Ib 期研究

Wang, Jiayu; Liu, Yunjiang; Zhang, Qingyuan; Li, Wei; Feng, Jifeng; Wang, Xiaojia; Fang, Jianmin; Han, Yiqun; Xu, Binghe

The effect of platelet-rich fibrin on the biological properties of urothelial cells

富血小板纤维蛋白对尿路上皮细胞生物学特性的影响

Shaohua Hu, Zhenli Zhao, Zhisheng Wan, Weizhen Bu, Songqiang Chen, Tianhong Han, Yiqun Lu

Development of graded prognostic assessment for breast Cancer brain metastasis incorporating extracranial metastatic features: a retrospective analysis of 284 patients

建立包含颅外转移特征的乳腺癌脑转移分级预后评估体系:一项对284例患者的回顾性分析

Wang, Yan; Xu, Hangcheng; Sa, Qiang; Li, Li; Han, Yiqun; Wu, Yun; Zhou, Yiran; Xu, Binghe; Wang, Jiayu

Docetaxel plus S-1 versus docetaxel plus capecitabine as first-line treatment for advanced breast cancer patients: a prospective randomized phase II study

多西他赛联合S-1与多西他赛联合卡培他滨作为晚期乳腺癌患者一线治疗方案的比较:一项前瞻性随机II期研究

Abudureheiyimu, Nilupai; Wu, Yun; Li, Qing; Zhang, Pin; Ma, Fei; Yuan, Peng; Luo, Yang; Fan, Ying; Chen, Shanshan; Cai, Ruigang; Li, Qiao; Han, Yiqun; Xu, Hangcheng; Wang, Yan; Wang, Jiayu; Xu, Binghe